| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
Correspondence to: Gregory W. Albers, MD, Stanford University Medical Center, Stanford Stroke Center, 701 Welch Rd, Building B, Suite 325, Palo Alto, CA 94304-1705
This chapter about treatment and prevention of stroke is part of the 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients’ values may lead to different choices (for a full understanding of the grading see Guyatt et al). Among the key recommendations in this chapter are the following: For patients with acute ischemic stroke (AIS), we recommend administration of IV tissue plasminogen activator (tPA), if treatment is initiated within 3 h of clearly defined symptom onset (Grade 1A). For patients with extensive and clearly identifiable hypodensity on CT, we recommend against thrombolytic therapy (Grade 1B). For unselected patients with AIS of > 3 h but < 6 h, we suggest clinicians not use IV tPA (Grade 2A). For patients with AIS, we recommend against streptokinase (Grade 1A) and suggest clinicians not use full-dose anticoagulation with IV or subcutaneous heparins or heparinoids (Grade 2B). For patients with AIS who are not receiving thrombolysis, we recommend early aspirin therapy, 160 to 325 mg qd (Grade 1A). For AIS patients with restricted mobility, we recommend prophylactic low-dose subcutaneous heparin or low molecular weight heparins or heparinoids (Grade 1A); and for patients who have contraindications to anticoagulants, we recommend use of intermittent pneumatic compression devices or elastic stockings (Grade 1C). In patients with acute intracerebral hematoma, we recommend the initial use of intermittent pneumatic compression (Grade 1C+). In patients with noncardioembolic stroke or transient ischemic attack (TIA) [ie, atherothrombotic, lacunar or cryptogenic], we recommend treatment with an antiplatelet agent (Grade 1A) including aspirin, 50 to 325 mg qd; the combination of aspirin and extended-release dipyridamole, 25 mg/200 mg bid; or clopidogrel, 75 mg qd. In these patients, we suggest use of the combination of aspirin and extended-release dipyridamole, 25/200 mg bid, over aspirin (Grade 2A) and clopidogrel over aspirin (Grade 2B). For patients who are allergic to aspirin, we recommend clopidogrel (Grade 1C+). In patients with atrial fibrillation and a recent stroke or TIA, we recommend long-term oral anticoagulation (target international normalized ratio, 2.5; range, 2.0 to 3.0) [Grade 1A]. In patients with venous sinus thrombosis, we recommend unfractionated heparin (Grade 1B) or low molecular weight heparin (Grade 1B) over no anticoagulant therapy during the acute phase.
Key Words: antithrombotic • prophylaxis • stroke • tissue plasminogen activator
This article has been cited by other articles:
|
|
 |
|
  J. S. Ross, S. Keyhani, P. S. Keenan, S. M. Bernheim, J. D. Penrod, K. S. Boockvar, A. D. Federman, H. M. Krumholz, and A. L. Siu Use of Recommended Ambulatory Care Services: Is the Veterans Affairs Quality Gap Narrowing? Arch Intern Med, May 12, 2008; 168(9): 950 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. LaBresh, M. J. Reeves, M. R. Frankel, D. Albright, and L. H. Schwamm Hospital Treatment of Patients With Ischemic Stroke or Transient Ischemic Attack Using the "Get With The Guidelines" Program Arch Intern Med, February 25, 2008; 168(4): 411 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Liao Secondary Prevention of Stroke and Transient Ischemic Attack: Is More Platelet Inhibition the Answer? Circulation, March 27, 2007; 115(12): 1615 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gosk-Bierska, W. Wysokinski, R. D. Brown Jr, K. Karnicki, D. Grill, H. Wiste, E. Wysokinska, and R. D. McBane II Cerebral venous sinus thrombosis: Incidence of venous thrombosis recurrence and survival. Neurology, September 12, 2006; 67(5): 814 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Malani and H. Ammar Cryptogenic stroke and patent foramen ovale. Ann Intern Med, September 5, 2006; 145(5): 393 - 394. [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Thomas, L. H. Schwamm, and M. H. Lev Case records of the Massachusetts General Hospital. Case 16-2006. A 72-year-old woman admitted to the emergency department because of a sudden change in mental status. N. Engl. J. Med., May 25, 2006; 354(21): 2263 - 2271. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, E. H. Bradley, and S. H. Busch Use of health care services by lower-income and higher-income uninsured adults. JAMA, May 3, 2006; 295(17): 2027 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.G. Gonzalez Imaging-guided acute ischemic stroke therapy: From "time is brain" to "physiology is brain". AJNR Am. J. Neuroradiol., April 1, 2006; 27(4): 728 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ovbiagele, N. K. Hills, J. L. Saver, S. C. Johnston, and for the CASPR Investigators Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA Neurology, February 14, 2006; 66(3): 313 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sanossian, J. L. Saver, V. Rajajee, S. L. Selco, D. Kim, T. Razinia, and B. Ovbiagele Premorbid antiplatelet use and ischemic stroke outcomes Neurology, February 14, 2006; 66(3): 319 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. O'Donnell, E. Berge, and P. M. Sandset Are There Patients With Acute Ischemic Stroke and Atrial Fibrillation That Benefit From Low Molecular Weight Heparin? Stroke, February 1, 2006; 37(2): 452 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Bosson and J. Labarere Determining indications for care common to competing guidelines by using classification tree analysis: application to the prevention of venous thromboembolism in medical inpatients. Med Decis Making, January 1, 2006; 26(1): 63 - 75. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Fisher Results of the Management of Atherothrombosis With Clopidogrel in High-Risk Patients Trial: Implications for the Neurologist Arch Neurol, January 1, 2006; 63(1): 20 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Kizer and R. B. Devereux Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N. Engl. J. Med., December 1, 2005; 353(22): 2361 - 2372. [Full Text] [PDF]
|
|
|
|
|
|
B. Bates, J. Y. Choi, P. W. Duncan, J. J. Glasberg, G. D. Graham, R. C. Katz, K. Lamberty, D. Reker, and R. Zorowitz Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: Executive Summary Stroke, September 1, 2005; 36(9): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Norris Antiplatelet Agents in Secondary Prevention of Stroke: A Perspective Stroke, September 1, 2005; 36(9): 2034 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Jamieson, A. Parekh, and M. D. Ezekowitz Review of Antiplatelet Therapy in Secondary Prevention of Cerebrovascular Events: A Need for Direct Comparisons Between Antiplatelet Agents Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2005; 10(3): 153 - 161. [Abstract] [PDF]
|
|
|
|
|
|
L. B. Goldstein and D. L. Simel Is This Patient Having a Stroke? JAMA, May 18, 2005; 293(19): 2391 - 2402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. Rickles Thrombolytic (fibrinolytic) drugs and progress in treating cardiovascular disease FASEB J, April 1, 2005; 19(6): 671 - 671. [Full Text] [PDF]
|
|
|
|
 |
|
 P Amarenco Patent foramen ovale and the risk of stroke: smoking gun guilty by association? Heart, April 1, 2005; 91(4): 441 - 443. [Full Text] [PDF]
|
|
|
|
|
|
H. Tran and S. S. Anand Oral Antiplatelet Therapy--Reply JAMA, February 16, 2005; 293(7): 794 - 795. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Bernstein and G. W. Albers Oral Antiplatelet Therapy JAMA, February 16, 2005; 293(7): 793 - 794. [Full Text] [PDF]
|
|
|
|
 |
|
 Guidelines on Antithrombotic and Thrombolytic Therapy for Stroke Journal Watch Neurology, January 27, 2005; 2005(127): 1 - 1. [Full Text]
|
|
|
|
 |
|
 T. L. Ortel Thrombosis and the Antiphospholipid Syndrome Hematology, January 1, 2005; 2005(1): 462 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Amarenco and G. A. Donnan Should the MATCH Results Be Extrapolated to All Stroke Patients and Affect Ongoing Trials Evaluating Clopidogrel Plus Aspirin? Stroke, November 1, 2004; 35(11): 2606 - 2608. [Full Text] [PDF]
|
|
|
|
|
|
M. S.V. Elkind Implications of stroke prevention trials: Treatment of global risk Neurology, July 12, 2005; 65(1): 17 - 21. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
